NCT03431896Completed
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
Source: ClinicalTrials.gov · Last updated 12 Mar 2026
Brief summary (registry, in English)
This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 37 (actual)
- First submitted
- 7 Feb 2018
- Start date
- 1 Feb 2018
- Primary completion date
- 9 Mar 2026
- Lead sponsor
- The Cleveland Clinic
- Diseases
- Amyloidosis
- NCT number
- NCT03431896
What you commit to
- Study type: Observational
- Participants enrolled: 37
- From 1 Feb 2018 to the primary completion date, 9 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with ATTR amyloidosis identified as wild-type.
Who the study is looking for
- Patients with known hereditary ATTR amyloidosis genetic mutations as identified by genetic testing.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.